Anika Therapeutics Files Definitive Proxy Statement
Ticker: ANIK · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 898437
| Field | Detail |
|---|---|
| Company | Anika Therapeutics, Inc. (ANIK) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Anika's proxy statement is out for the June 20 meeting - vote your shares!
AI Summary
Anika Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on April 28, 2025, for its annual meeting on June 20, 2025. The filing outlines information for shareholders regarding the company's governance, executive compensation, and proposals to be voted on at the meeting. Key details will be provided to shareholders to inform their voting decisions.
Why It Matters
This filing provides shareholders with crucial information needed to vote on company matters, including director elections and executive compensation, impacting corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently signal new risks.
Key Numbers
- 20250620 — Annual Meeting Date (Shareholders will vote on company matters at this date.)
- 20250428 — Filing Date (The date Anika Therapeutics filed its definitive proxy statement.)
Key Players & Entities
- Anika Therapeutics, Inc. (company) — Filer of the DEF 14A
- 0001140361-25-016082 (dollar_amount) — Accession Number for the filing
- 20250428 (dollar_amount) — Filing Date
- 20250620 (dollar_amount) — Conformed Period of Report (Annual Meeting Date)
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing detailed information on matters to be voted upon.
When is the Anika Therapeutics shareholder meeting scheduled?
The conformed period of report is June 20, 2025, indicating the likely date for the shareholder meeting.
Who is the filer of this document?
The filer is Anika Therapeutics, Inc., as indicated by the company data section.
What is the company's primary business according to the SIC code?
The Standard Industrial Classification (SIC) code is 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
What is the company's fiscal year end?
The company's fiscal year ends on December 31 (1231).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Anika Therapeutics, Inc. (ANIK).